These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

841 related articles for article (PubMed ID: 22521881)

  • 1. Ticagrelor: oral reversible P2Y(12) receptor antagonist for the management of acute coronary syndromes.
    Cheng JW
    Clin Ther; 2012 Jun; 34(6):1209-20. PubMed ID: 22521881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ticagrelor: a review of its use in adults with acute coronary syndromes.
    Dhillon S
    Am J Cardiovasc Drugs; 2015 Feb; 15(1):51-68. PubMed ID: 25672642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel antiplatelet agent ticagrelor in the management of acute coronary syndrome.
    Ramaraj R; Movahed MR; Hashemzadeh M
    J Interv Cardiol; 2011 Jun; 24(3):199-207. PubMed ID: 21198849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ticagrelor: a novel reversible oral antiplatelet agent.
    Nawarskas JJ; Clark SM
    Cardiol Rev; 2011; 19(2):95-100. PubMed ID: 21285670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating the risk-benefit profile of the direct-acting P2Y(12) inhibitor ticagrelor in acute coronary syndromes.
    Husted S
    Postgrad Med; 2011 Nov; 123(6):79-90. PubMed ID: 22104457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial.
    Held C; Asenblad N; Bassand JP; Becker RC; Cannon CP; Claeys MJ; Harrington RA; Horrow J; Husted S; James SK; Mahaffey KW; Nicolau JC; Scirica BM; Storey RF; Vintila M; Ycas J; Wallentin L
    J Am Coll Cardiol; 2011 Feb; 57(6):672-84. PubMed ID: 21194870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ticagrelor--a new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors?
    Kowalczyk M; Banach M; Mikhailidis DP; Hannam S; Rysz J
    Med Sci Monit; 2009 Dec; 15(12):MS24-30. PubMed ID: 19946242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial.
    James S; Akerblom A; Cannon CP; Emanuelsson H; Husted S; Katus H; Skene A; Steg PG; Storey RF; Harrington R; Becker R; Wallentin L
    Am Heart J; 2009 Apr; 157(4):599-605. PubMed ID: 19332184
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ticagrelor. Acute coronary syndromes: nothing new.
    Prescrire Int; 2011 Oct; 20(120):229-33. PubMed ID: 21970081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of ticagrelor: a reversible P2Y12 receptor antagonist.
    Anderson SD; Shah NK; Yim J; Epstein BJ
    Ann Pharmacother; 2010 Mar; 44(3):524-37. PubMed ID: 20124464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. P2Y₁₂ receptor inhibitors: integrating ticagrelor into the management of acute coronary syndrome.
    Crouch MA; Colucci VJ; Howard PA; Spinler SA
    Ann Pharmacother; 2011 Sep; 45(9):1151-6. PubMed ID: 21852599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study.
    Alexopoulos D; Galati A; Xanthopoulou I; Mavronasiou E; Kassimis G; Theodoropoulos KC; Makris G; Damelou A; Tsigkas G; Hahalis G; Davlouros P
    J Am Coll Cardiol; 2012 Jul; 60(3):193-9. PubMed ID: 22789884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging oral antiplatelet therapies for acute coronary syndromes.
    Pollack CV
    Hosp Pract (1995); 2010 Nov; 38(4):29-37. PubMed ID: 21068524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging antiplatelet therapy for coronary artery disease and acute coronary syndrome.
    Packard KA; Campbell JA; Knezevich JT; Davis EM
    Pharmacotherapy; 2012 Mar; 32(3):244-73. PubMed ID: 22392457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ticagrelor: the first novel reversible P2Y(12) inhibitor.
    Htun WW; Steinhubl SR
    Expert Opin Pharmacother; 2013 Feb; 14(2):237-45. PubMed ID: 23268703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduction in first and recurrent cardiovascular events with ticagrelor compared with clopidogrel in the PLATO Study.
    Kohli P; Wallentin L; Reyes E; Horrow J; Husted S; Angiolillo DJ; Ardissino D; Maurer G; Morais J; Nicolau JC; Oto A; Storey RF; James SK; Cannon CP
    Circulation; 2013 Feb; 127(6):673-80. PubMed ID: 23277305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implications of variability in definition and reporting of major bleeding in randomized trials of oral P2Y12 inhibitors for acute coronary syndromes.
    Quinlan DJ; Eikelboom JW; Goodman SG; Welsh RC; Fitchett DH; Théroux P; Mehta SR
    Eur Heart J; 2011 Sep; 32(18):2256-65. PubMed ID: 21624900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors contributing to the lower mortality with ticagrelor compared with clopidogrel in patients undergoing coronary artery bypass surgery.
    Varenhorst C; Alström U; Scirica BM; Hogue CW; Åsenblad N; Storey RF; Steg PG; Horrow J; Mahaffey KW; Becker RC; James S; Cannon CP; Brandrup-Wognsen G; Wallentin L; Held C
    J Am Coll Cardiol; 2012 Oct; 60(17):1623-30. PubMed ID: 23021325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ticagrelor: from discovery to Phase III clinical trial.
    Siller-Matula JM; Jilma B
    Future Cardiol; 2010 Nov; 6(6):753-64. PubMed ID: 21142630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ticagrelor: a review of its use in the management of acute coronary syndromes.
    Deeks ED
    Drugs; 2011 May; 71(7):909-33. PubMed ID: 21568367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.